Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.
OBJECTIVE
To evaluate and compare the influence of dietary elements on cancer progression, chemotherapy efficacy, and toxicity, particularly severe, late-onset diarrhea related to irinotecan (CPT-11) treatment.


METHODS
We used laboratory rats fed a standardized basal diet, Ward colon tumor, and CPT-11 therapy for the study of CPT-11-induced diarrhea. Dietary interventions were selected from nutrients already established to modify other forms of colitis and which have been hypothesized to mitigate chemotherapy-induced gastrointestinal injury (glutamine, n-3 fatty acids, prebiotic oligosaccharides). Animals adapted to test diets were treated with CPT-11 at the maximum tolerated dose (125 mg/kg x 3 days) and diarrhea was followed continuously for 1 week.


RESULTS
The inclusion of n-3 fatty acids in the diet (5%, w/w of total fat) suppressed tumor growth and enhanced CPT-11's efficacy; this treatment did not affect the incidence or severity of diarrhea. By contrast, oral glutamine bolus (0.75 g/kg) administered prior to each CPT-11 treatment reduced the incidence of severe diarrhea (34.1 +/- 4.7% versus 53.8 +/- 4.2%, P < 0.005) and decreased the area under the curve of diarrhea score (16.5 +/- 1.0 versus 18.8 +/- 0.5, P < 0.05). Identical results were obtained with i.v. bolus glutamine administration. Glutamine treatment did not alter CPT-11's antitumor efficacy. The addition of prebiotic oligosaccharides to the diet (8%, w/w of diet) did not mitigate the severity of diarrhea, and it raised the activity of beta-glucuronidase in cecal contents, a key bacterial enzyme mediating CPT-11-related intestinal toxicity.


CONCLUSIONS
Our experiments suggest that glutamine and n-3 fatty acids might be potentially useful adjuncts to CPT-11 treatment.
Xue
Hongyu
H
Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Sawyer
Michael B
MB
Field
Catherine J
CJ
Dieleman
Levinus A
LA
Baracos
Vickie E
VE
D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D003967:Diarrhea / Q000139:chemically induced* / Q000517:prevention & control; D004032:Diet; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D018565:Food-Drug Interactions; D005973:Glutamine / Q000008:administration & dosage*; D000077146:Irinotecan; D009844:Oligosaccharides / Q000008:administration & dosage*; D019936:Probiotics / Q000008:administration & dosage; D051381:Rats
D015525:Fatty Acids, Omega-3; D009844:Oligosaccharides; D005973:Glutamine; D000077146:Irinotecan; D002166:Camptothecin